Quoin Pharmaceuticals Launches Insightful NETHERTON NOW Video
Recently, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) introduced an enlightening episode of their NETHERTON NOW video series. This episode features the insights of Professor Jemima Mellerio, a distinguished expert in genetic skin disorders and a consultant dermatologist.
In this engaging video, Professor Mellerio sheds light on the critical challenges posed by Netherton Syndrome. This condition primarily affects infants and young children, creating significant hurdles for both the patients and their families. She emphasizes that Netherton Syndrome is more than just a skin condition; it has far-reaching implications for health and wellbeing.
“Netherton Syndrome is classified as a skin disease called ichthyosis. It's a genetic condition and we don't currently have a cure for it,” Professor Mellerio explained. This serious medical issue, particularly threatening to young children, involves associated mortality risks, which underscores the urgency for effective interventions.
The experienced professor elaborates on the lifelong implications of living with Netherton Syndrome. “This is a lifelong condition that requires intensive treatment every single day,” she notes, expressing her hope for future advancements in the field. With more research and targeted treatments on the horizon, there is newfound optimism for those affected.
Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals, highlighted how crucial Professor Mellerio’s contributions are to the NETHERTON NOW series. Her clinical expertise and firsthand experience with genetic skin diseases highlight the severity of Netherton Syndrome and the pressing need for better treatment options.
In tandem with the video release, Quoin Pharmaceuticals has recently received some exciting news from regulatory bodies. The U.S. Food and Drug Administration (FDA) has granted their primary product candidate, QRX003, Rare Pediatric Disease Designation for the treatment of Netherton Syndrome. Along with this recognition, the European Medicines Agency (EMA) has also awarded Orphan Drug status, which reflects the seriousness of the condition and the challenges it poses in pediatric care.
“The experiences shared by Professor Mellerio speak directly to the challenges that children and families face from birth when living with Netherton Syndrome,” stated Dr. Michael Myers, CEO of Quoin Pharmaceuticals. The urgency felt by the team at Quoin resonates in their commitment to develop QRX003 as a viable treatment option. The FDA's recent designation further emphasizes the critical nature of this issue.
The ongoing NETHERTON NOW campaign is part of Quoin’s broader mission to elevate patient voices, enhance awareness, and foster education about Netherton Syndrome. The full video with Professor Mellerio can be viewed on Netherton Now's website, providing valuable perspectives on this challenging condition.
Understanding QRX003
QRX003 represents a significant advancement in treating Netherton Syndrome. This topical lotion employs a proprietary delivery technology that includes a broad-spectrum serine protease inhibitor, acting similarly to a protein vital for maintaining skin health. For individuals with Netherton Syndrome, the absence of this protein results in severe skin-related issues, making QRX003 a potentially transformative solution.
This product aims to optimize skin behavior, improving the skin's barrier function and providing much-needed relief for patients suffering from this debilitating condition. As Quoin moves forward with clinical trials, the focus remains on crafting effective treatments that can genuinely make a difference in the lives of those affected.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. stands as a pioneering entity committed to the development and commercialization of treatments for rare and orphan diseases. The company’s innovative pipeline currently includes four promising products targeting a variety of conditions, underscoring its dedication to addressing unmet medical needs in the healthcare community worldwide. Quoin’s focus also extends to less common disorders, ensuring that patients receive the care they deserve. To stay updated, potential patients and interested parties are encouraged to visit Quoin’s official website.
Frequently Asked Questions
What is the NETHERTON NOW series?
The NETHERTON NOW series is an initiative by Quoin Pharmaceuticals aimed at raising awareness and providing education about Netherton Syndrome.
Who is Professor Jemima Mellerio?
Professor Mellerio is an expert in dermatology and genetic skin disorders, featured in Quoin’s latest video discussing Netherton Syndrome.
What is QRX003?
QRX003 is a topical lotion developed by Quoin Pharmaceuticals aimed at treating Netherton Syndrome by improving the skin barrier function.
What designations has QRX003 received?
QRX003 has received Rare Pediatric Disease Designation from the FDA and Orphan Drug status from the EMA.
How can I learn more about Quoin Pharmaceuticals?
You can visit Quoin Pharmaceuticals' official website for information on their pipeline, clinical trials, and updates regarding their initiatives.
